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Abstract
Introduction: Strategies to improve the efficacy of endocrine agents in breast cancer (BC) therapy and to delay
the onset of resistance include concomitant targeting of the estrogen receptor alpha (ER) and the mammalian
target of rapamycin complex 1 (mTORC1), which regulate cell-cycle progression and are supported by recent
clinical results.
Methods: BC cell lines expressing aromatase (AROM) and modeling endocrine-sensitive (MCF7-AROM1) and
human epidermal growth factor receptor 2 (HER2)-dependent de novo resistant disease (BT474-AROM3) and long-
term estrogen-deprived (LTED) MCF7 cells that had acquired resistance associated with HER2 overexpression were
treated in vitro and as subcutaneous xenografts with everolimus (RAD001-mTORC1 inhibitor), in combination with
tamoxifen or letrozole. End points included proliferation, cell-cycle arrest, cell signaling, and effects on ER-mediated
transactivation.
Results: Everolimus caused a concentration-dependent decrease in proliferation in all cell lines, which was
associated with reductions in S6 phosphorylation. Everolimus plus letrozole or tamoxifen enhanced the
antiproliferative effect and G1-accumulation compared with monotherapy, as well as increased phosphorylation
(Ser10) and nuclear accumulation of p27 and pronounced dephosphorylation of Rb. Sensitivity was greatest to
everolimus in the LTED cells but was reduced by added estrogen. Increased pAKT occurred in all circumstances
with everolimus and, in the BT474 and LTED cells, was associated with increased pHER3. Decreased ER
transactivation suggested that the effectiveness of everolimus might be partly related to interrupting cross-talk
between growth-factor signaling and ER. In MCF7-AROM1 xenografts, letrozole plus everolimus showed a trend
toward enhanced tumor regression, versus the single agents. In BT474-AROM3 xenografts, everolimus alone was
equally effective at reducing tumor volume as were the combination therapies.
Conclusions: The results provide mechanistic support for recent positive clinical data on the combination of
everolimus and endocrine therapy, as well as data on potential routes of escape via enhanced HER2/3 signaling.
This merits investigation for further improvements in treatment efficacy.
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Introduction
About 80% of primary breast cancer (BC) is estrogen-
receptor alpha positive (ER+) and proliferates in response
to estrogen (E). E mediates its effect by binding to ER,
which in turn regulates transcription of target genes con-
trolling proliferation and cell survival. Clinically, patients
are treated with endocrine agents such as tamoxifen,
which competes with E for the ER or aromatase inhibi-
tors (AIs), which block the conversion of androgens to E.
The most effective approach in postmenopausal patients
is with AIs, but, as with other treatments, resistance to
these agents develops in many cases. Studies in model
systems indicate that this resistance may often depend on
the acquisition of enhanced cross-talk between ER and
growth-factor pathways that allows the disease to cir-
cumvent the need for steroid hormones [1].
In BC, the PI3K/AKT pathway modulates responses to
signals, communicated through the ER and the HER family
of receptors [2]. This pathway is important in the clinical
sensitivity of BC to antiendocrine therapy [3-6]. In vitro
studies have implicated AKT in the ligand-independent
phosphorylation of the ER and subsequent resistance to
tamoxifen [7,8]. Similarly, elevated levels of AKT have been
shown to change the genome-wide binding pattern of ER,
effectively altering the ER program [9]. These data suggest
that signaling partners downstream of PI3K/AKT may pro-
vide potential therapeutic targets.
One rational possibility is mTOR, which exists in
mammalian cells as two protein complexes; mTORC1
(containing raptor) and mTORC2 (containing rictor).
mTORC1 regulates cell-cycle progression (the key effec-
tors of endocrine therapy) by enhancing translation
initiation and/or the stability of cell-cycle regulatory
proteins, such as D-type cyclins [10], c-myc [11], p27Kip1
[12], and p21Waf1/Cip1 [13]. The two direct targets of
mTORC1 are p70 S6 kinase and 4E-BP1, which mediate
its effect on protein translation. Activation of mTORC1,
in response to nutrient availability and activation of the
PI3K/AKT pathway, results in the hyperphosphorylation
of 4E-BP1 and the release of eIF4E, which, together with
eIF4G, form a functional eIF4F mRNA cap binding
complex and initiates translation. p70 S6 phosphorylates
the 40S ribosomal subunit protein S6 and stimulates the
translation of the 5’ oligopyrimidine tract containing
mRNAs [14]. Several of these cell-cycle regulators are
dysregulated in BC, including eIF-4E [15], p27 [16],
D-type cyclins [17], and c-myc [18]. Hence, mTORC1
may provide a novel target for the treatment of breast
tumors that are endocrine resistant [19].
Evidence suggests that the mTORC1 inhibitor rapa-
mycin, and its derivatives (rapalogs), may have some
antitumorogenic activity [19,20]. Rapamycins/rapalogs
are allosteric inhibitors that, when in complex with the
immunophilin FKBP12, target the FRB domain adjacent
to the catalytic site of mTORC1, leading to inactivation
of p70 S6 kinase and activation of 4E-BP1 as a repressor
of cap-dependent translation; resulting in the suppres-
sion of global protein synthesis [21]. Until recently,
rapalogs showed modest clinical activity in BC [22,23].
Lately, however, two clinical studies reported substan-
tially greater activity of the rapalog everolimus
(RAD001) in the metastatic setting, when administered
after prior treatment with an AI. First, in the TAMRAD
study, median time to tumor progression (TTP) was 4.5
months (95% confidence interval (CI), 3.7 to 8.7) with
tamoxifen and 8.5 months (95% CI, 6.01 to 13.9) with
everolimus plus tamoxifen [24]. BOLERO-2 found that
the median TTP with exemestane alone of 4.1 months
after failure of nonsteroidal AI was extended to 10.6
months, a result so positive that it required early cessa-
tion of the trial [25].
We report here that in isogenic derivatives of MCF7
cells, the activity of everolimus is enhanced after acqui-
sition of resistance to E-deprivation, together with
mechanistic data that improve understanding of this
enhanced activity. We also report xenograft studies of
the combination of everolimus (RAD001) with the AI
letrozole and parallel studies in the ER+ BT474 cell line,
whose endocrine resistance depends on HER2 amplifica-
tion that is associated with response to rapalogs [26].
The results provide mechanistic support for recent posi-
tive clinical data on the combination of RAD001 and
endocrine therapy, as well as data on potential routes of
escape, via enhanced HER2/3 signaling, that merit inves-
tigation for further improvements in treatment efficacy.
Methods
Antibodies
These companies provided the following substances:
Cell Signaling Technology, New England Biolabs, Hert-
forshire, UK (phospho-AKTser473, AKT, ERK1/2, phos-
pho-ERaser118, phospho-ERaser167, phospho-S6ser240/244,
phospho-HER3tyr1289, phospho-p27ser10, p27, phospho-
Rbser807/811, Cyclin D3); Millipore (phospho-HER2tyr1248,
HER2, HER3, IRS1, IRS2); Sigma, Poole, Dorset UK
(phospho-ERK1/2thr202/tyr204, actin); Santa Cruz Biotech-
nology, Santa Cruz, USA (IGF1Rb); Novacastra Labora-
tories, Newcastle upon Tyne, UK (ER). HRP-conjugated
secondary antibodies were obtained from Amersham
Pharmacia, Amersham UK. 17 b-Estradiol (E2) and 4-
hydroxytamoxifen (4-OH tamoxifen) were obtained
from Sigma Poole, Dorset, UK; RAD001 and letrozole
were synthesized in the laboratories of Novartis Pharma
AG, Basel, Switzerland. All chemicals, unless otherwise
stated, were molecular grade and purchased from Sigma,
Poole, Dorset UK. All tissue-culture-grade plastics were
purchased from Thermo Fisher Scientific Nunc, Leices-
tershire UK.
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Tissue culture
MCF7-AROM1 and BT474-AROM3 were derived from
parental cell lines (obtained from American Type Culture
Collection) to stably express CYP19 (AROM) [27,28].
These modified cell lines were given the suffix AROM to
distinguish them from the parental cells. AROM cells
were maintained in phenol red-containing RPMI 1640
medium containing 2 mM glutamine, 10 μg/ml insulin,
and 10% (vol/vol) fetal bovine serum (FBS) supplemented
with 1 mg/ml G418. MCF7 cells that had adapted to
long-term estrogen deprivation (LTED) were maintained
in phenol red-free RPMI 1640 medium containing 2 mM
glutamine, 10 μg/ml insulin supplemented with 10% (vol/
vol) dextran-coated charcoal-stripped FBS (DCC-FBS)
[29], referred to as DCC. For all experiments, cells lines
were stripped of steroids for 3 days before seeding by cul-
turing in DCC in the absence of insulin.
Cell-proliferation assays
Cell lines were seeded into 12-well plates at densities
between 1 and 4 × 104 cells per well. Cell monolayers
were left to acclimatize for 24 hours before treatment
with the drug combinations indicated for 6 days, with
daily changes. Cell number was determined by using a
Z1 Coulter Counter (Beckman Coulter, UK). The com-
bination effects between RAD001 and 4-OH-tamoxifen
or letrozole were analyzed by using isobolograms. To
determine the nature of the interaction between
RAD001 and letrozole or 4-OH-tamoxifen, combination
studies were performed by using Chou and Talalay’s
constant ratio combination design and quantified by
using Calcusyn software (BIOSOFT, Cambridge, UK)
[30]. The combination indices (CI; mean and SD) for
50%, 75%, and 90% growth inhibition were obtained by
using mutually nonexclusive Monte Carlo simulations,
and statistical tests were applied (unpaired, two-tailed
Student t test) to determine whether the CI values at
multiple effect levels were significantly different from
CI = 1. In this analysis, CI scores significantly lower
than 1 were defined as synergistic; CI > 1, as antagonis-
tic; and a CI = 1, as additive. Experiments were set up
in triplicate.
Transcription assay
Cell lines were seeded in 24-well plates at 7 × 104 cells
per well in DCC medium for all cell lines except BT474,
which was seeded at 1 × 105 cells per well. Twenty-four
hours later, monolayers were transfected with Fugene
(Roche, UK) with 0.1 μg of EREIItkluc and 0.1 μg of
pCH110 overnight, before treatment with the drugs
indicated. After 24 hours, luciferase (Promega, UK) and
b-galactosidase (Galacto Star; PE Biosystems, UK) activ-
ities were measured by using a luminometer.
Western blotting
Cell monolayers were extracted as described previously
[31]. Protein concentrations were quantified by using
BioRad protein assay kit (Bio Rad, UK). Proteins (50 μg)
were resolved with SDS-PAGE and transferred to nitro-
cellulose filters (Schleicher and Schuell, UK). Filters
were probed with specific antibodies as indicated.
Immune complexes were detected by using the Ultra-
Signal chemiluminescence kit from Pierce and Warriner
(Chester, UK).
Cell-cycle effects of RAD001 alone or in combination with
endocrine agents
Cells were seeded into 10-cm dishes. Monolayers were
treated with the drug combinations indicated for 24 hours.
Cells were pulse-labeled with 10 μM bromodeoxyuridine
for 2 hours and then fixed and stained with anti-bromo-
deoxyuridine-conjugated FITC (Becton Dickinson) and
propidium iodide. Fluorescence-activated cell signaling
(FACS) was used to analyze changes in the cell cycle. To
assess the effect on cell-cycle regulatory proteins, similarly
treated cell monolayers were lysed and subjected to immu-
noblotting at the same time.
Immunofluorescence
Cells were prepared as described previously [32]. After
24 hours of treatment with the drugs indicated, cells
were fixed and incubated with a monoclonal anti-
human p27 antibody (DakoCytomation), as previously
described [32]. Cells were then incubated in the pre-
sence of Alexa Fluor 488-conjugated goat anti-mouse
IgG secondary antibody (Molecular Probes), counter-
stained with TO-PRO-3 (Invitrogen), and mounted onto
glass slides by using Vectashield mounting medium
(Vector Laboratories). Images were collected sequen-
tially in two channels on a Leica TCS SP2 confocal
microscope (Milton Keynes, UK). The p27-positive
nuclei were counted in each image by using the count
tool in Adobe Photoshop CS6 Extended and were
expressed as a percentage of total nuclei present (repre-
sented by DAPI-stained nuclei). Values shown are mean
percentages ± standard deviation.
Human tumor xenografts
Experiments were carried out in accordance with Home
Office guidelines and approved by the Institute of Cancer
Research Ethics Committee. Female Ncr Foxhead nude
mice were kept under sterile conditions (eight per cage)
with free access to food and water. Mice were ovariecto-
mized and then allowed to acclimatize for 7 to 14 days.
MCF7 AROM 1 and BT474 AROM 3 xenografts were
initiated by inoculation of 100-μl cell suspension contain-
ing 107 cells in basement membrane matrix (Matrigel;
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BD Biosciences) into the right flank. Growth was main-
tained by androstenedione support through intradermal
injection of androstenedione pellets (dose, 1.5 mg over a
60-day period; Innovative Research of America, Sarasota,
FL, USA). Tumors were grown to approximately 7- to
8-mm diameter and assigned to treatment groups with
no statistically significant difference in mean volume
before treatment (Kruskal-Wallis ANOVA, MCF7
AROM 1, P = 0.14; and BT474-AROM3, P = 0.34). Mice
were continued with androstenedione support and ran-
domized to receive daily doses of vehicle (10% N-methyl-
pyrollidone (NMP)/90% polyethylene glycol (PEG300),
RAD001 (in 10% NMP/90% PEG300), tamoxifen (3.3 mg/
ml in 10% NMP/90% PEG300), letrozole (0.17 mg/ml in
10% NMP/90% PEG300), or RAD001 in combination
with tamoxifen or letrozole. All drugs were administered
by oral gavage and were given daily for a total of 24 days.
Tumor growth was assessed twice weekly in all con-
trol and treatment arms by caliper measurements of the
two largest diameters. Volumes were then calculated
according to the formula: a × b2 × π/6, where a and b
are orthogonal tumor diameters. Tumor volumes were
then expressed as fold change in volume at the start of
treatment.
Overall statistical difference was calculated by using
the Kruskal-Wallace test, and the statistical differences
between individual treatment arms was calculated by
using the Mann-Whitney test.
Results
Effect of RAD001 alone or in combination with endocrine
therapy on cell growth
To enable the study of an AI in combination with evero-
limus, we used our MCF-7 and BT474 cells that had
been genetically engineered to express aromatase
(MCF7-AROM1 and BT474-AROM3) [27,28] and pro-
vided 10 nM androstenedione as growth support. Our
long-term estrogen-deprived MCF7 cell line (LTED) was
used to model acquired resistance to an AI. These cells
show increased expression of HER2 but do not express
aromatase (see Additional File 1) [31].
RAD001 alone caused a concentration-dependent
decrease in proliferation in all the cell lines tested
(Figure 1A through 1F; black line on each graph). The
median inhibitory concentration (IC50) for RAD001 was
between 0.25 and 0.5 nM for MCF7-AROM1 in the pre-
sence of androstenedione and 0.5 nM for BT474-
AROM3 (Figure 1A-D, black line) in the presence of
androstenedione. The LTED cell line showed the great-
est sensitivity, with an IC50 of 0.2 nM in the absence of
exogenous E2 (Figure 1E, black line) versus 0.6 nM
RAD001 in the presence of E2 (Figure 1F, black line).
The effect of doubling concentrations of RAD001 in
combination with letrozole (100 nM) or 4-OH tamoxifen
(10 nM) was assessed; the concentrations of each of the
endocrine agents were close to their mean plasma levels
obtained at the recommended doses of 2.5 mg/day letro-
zole or 20 mg/day tamoxifen. It should be noted that
although 4-OH tamoxifen is a major active metabolite of
tamoxifen, other metabolites may contribute to the clinical
activity of this agent. Both letrozole and 4-OH tamoxifen
alone decreased proliferation compared with androstene-
dione in MCF7 AROM1 cells, and a modest extra benefit
was noted when added to RAD001 (Figure 1A and 1B).
BT474-AROM3 cells showed sensitivity to letrozole alone
but were resistant to 4-OH tamoxifen (Figure 1C and 1D).
Of note, the combination of letrozole or 4-OH tamoxifen
with doubling concentrations of RAD001 showed greater
efficacy than RAD001 alone.
The LTED cells were used to model the cessation of
AI at relapse by the addition of 0.01 nM E2. RAD001
was marginally more effective in the absence of added
E2 (IC50, 0.2 nM (Figure 1E) versus IC50 0.63 nM in the
presence of E2 (Figure 1F)). Similar to the BT474-
AROM3 cells, addition of 4-OH tamoxifen improved
the efficacy of RAD001 (Figure 1F).
We subsequently conducted formal assessment of the
interaction between letrozole and 4-OH tamoxifen with
RAD001. Calcusyn software was used to establish the IC50
dose of 4-OH tamoxifen, letrozole, and RAD001 for each
of the cell lines. These were then combined in equipotent
fixed-dose ratios. The antiproliferative effect of the drugs
at their IC50 values alone and in combination is shown in
Figure 2A through 2E. The tables are derived from equi-
potent doses of the drugs giving 50%, 75%, and 90%
growth inhibition. Although from our initial analyses,
enhancement of the antiproliferative effect of RAD001 was
seen when combined with the endocrine agents in all cir-
cumstances (Figure 1), formal estimates showed a variety
of interactions. In the MCF7-AROM1 cells, RAD001 was
predominantly synergistic when used with letrozole, as
indicated by combination indices (CIs) < 1 at 75% and
90% growth inhibition (Figure 2A). However, RAD001 was
antagonistic with 4-OH tamoxifen at all doses tested CI >
1 (Figure 2B). In contrast, strong synergy was seen with 4-
OH tamoxifen in the LTED cells with CIs < 1 at 75% and
90% growth inhibition (Figure 2E). The HER2-amplified
BT474-AROM3 cells showed synergy with almost all
doses of both letrozole (Figure 2C) and 4-OH tamoxifen
(Figure 2D).
RAD001 inhibits mTORC1 signaling but increases pAKT,
pERK1/2, and pHER3
To investigate the effect of RAD001 on cell signaling,
MCF7-AROM1, BT474-AROM3, and LTED cells were
treated for 24 hours with RAD001 ± letrozole or 4-OH
tamoxifen (Figure 3). Phosphorylation of S6 at Ser240/244
was dramatically suppressed by RAD001 alone or in
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Figure 1 Antiproliferative effects of RAD001, 4-OH tamoxifen, and letrozole in endocrine sensitive and resistant breast cancer cell
lines. Cells were treated with a standard concentration of androstenedione (10 nM) and doubling concentrations of RAD001 ± letrozole (100
nM) or 4OH-tamoxifen (10 nM). After 6 days of treatment, cell numbers were analyzed by using a Coulter counter. (A, B) MCF7-AROM1.
(C, D) BT474-AROM3. (E) LTED cells treated with doubling concentrations of RAD001 in the absence of exogenous E2. (F) LTED cells treated with
a standard concentration of E2 (0.01 nM) and doubling concentrations of RAD001 ± 4-OH tamoxifen (10 nM). Data are expressed as fold-change
relative to DCC-FBS to show the increase in proliferation in response to androstenedione. Data shown are representative of three independent
experiments. Error bars represent ± SEM.
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Figure 2 Formal assessment of RAD001 combination index. Cell lines were treated as described with IC50 concentrations of each drug alone
or in combination, as indicated in the graphs. For Combination Index Tables shown, each graph MCF7-AROM1 (A, B) and BT474-AROM3 (C, D)
were treated over a 6-day period in the presence of 10 nM androstendione with equipotent doses of letrozole, 4-OH tamoxifen, and RAD001. In
the case of LTED cells (E), similar analyses were carried out in the presence of E2 (0.01 nM), RAD001, and 4-OH tamoxifen at fixed ratios of the
two agents. CIs were derived by using Calcusyn software, and significance was calculated as detailed in Methods.
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Effect on IGF1R signalling pathways
Actin Actin
Actin
1.11 0.87 0.55 0.78 0.73 0.96 0.81 0.72
0.84 0.61 0.35 0.47 0.67 0.50 0.37 0.49
0.19 0.22 0.20 0.12 0.13 0.09 0.20 0.32














































0.91 1.75 1.31 1.55 1.17 1.46 0.98 1.31
1.36 2.33 1.90 2.00 1.79 1.95 1.63 1.77
0.26 0.99 0.84 1.13 0.81 1.10 0.51 0.93











0.92 1.49 0.40 0.46 0.60 0.64
1.65 1.77 1.57 1.57 1.69 1.53
0.34 0.54 0.45 0.75 0.36 0.92














































0.12 0.36 0.03 0.55 0.06 0.15 0.03 0.22
0.36 1.16 0.19 0.88 0.19 0.89 0.32 1.11
0.50 0.00 0.49 0.00 0.42 0.00 0.42 0.00
0.37 1.13 0.57 1.04 0.29 1.03 0.34 1.01
1.38 2.59 1.02 1.52 0.47 0.47 1.10 0.97




























































0.09 0.31 0.06 0.20 0.08 0.81
1.21 1.03 1.26 1.01 0.96 0.76














































0.27 0.29 0.73 0.97 0.32 0.24 0.53 0.50
0.18 0.13 0.73 0.49 0.16 0.08 0.32 0.18
0.18 0.16 0.66 0.58 0.21 0.14 0.27 0.23
1.38 1.29 1.26 1.29 0.69 0.86
0.46 0.77 0.71 0.85 0.67 0.68
0.60 0.68 0.71 0.81 0.62 0.66
Figure 3 RAD001 in combination with endocrine therapy induces increased pAKT, pERK1/2, and pHER3. Steroid-depleted aromatase-
expressing cells were treated for 24 hours with the drug combinations indicated. Whole-cell extracts were assessed for expression of various
proteins indicated by using immunoblotting. (A) Effect of RAD001 alone or in combination with the endocrine agents on S6 kinase, ERK1/2, and
AKT for the selected cell lines. (B) Effect of RAD001 on IGF1-R signalling. (C) Effect of RAD001 on HER signaling. Figures below each panel, where
shown, represent semiquantitative changes in protein expression relative to actin.
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combination with the endocrine agents in all cell lines
(Figure 3A). In contrast, RAD001 alone or in combina-
tion increased the level of pAKT in each of the cell lines.
The combination of RAD001 and androstenedione ±
4-OH tamoxifen or letrozole increased pERK1/2 in
MCF7-AROM1 cells (Figure 3A). Similarly, albeit to a
far lesser extent, RAD001 increased pERK1/2 in both
the DCC- and androstenedione-treated BT474-AROM3
cells. Letrozole treatment suppressed pERK1/2 similar
to the MCF7-AROM1, but no increase in expression of
pERK1/2 was seen with the addition of RAD001. Of
note, altered expression of pERK1/2 was not evident in
the LTED cells (Figure 3A). As increases in pAKT have
been associated with alterations in IGF-1R signaling
[33], we assessed the effect of RAD001 ± endocrine
therapy on expression of IGF-1Rb, IRS1, and IRS2
(Figure 3B). The MCF7-AROM1 cell line showed
increased levels of IGF-1Rb, IRS1, and IRS2 in response
to androstenedione, which were suppressed by letrozole
and 4-OH tamoxifen. Addition of RAD001 suppressed
further the levels of IRS1, an observation in contrast to
that previously reported [33]. At present, this observation
remains unexplained. IRS2 remained unchanged in
response to RAD001 in the MCF7-AROM1. Addition of
RAD001 to LTED cells caused a slight, but expected,
increase in IRS1 and not IRS2 (Figure 3B). IGF-1R
expression in the BT474-AROM3 cells was extremely
low, and neither IRS1 nor IRS2 was detectable with Wes-
tern blot (data not shown). Assessment of the impact of
RAD001 on HER signaling (Figure 3C) showed that
RAD001 ± endocrine therapy increased pHER2, pHER3,
total HER2, and HER3 expression in the BT474-AROM3.
The LTED cells showed a marked increase in pHER2 and
total HER2 in response to RAD001 in the absence of E2.
In keeping with the BT474-AROM3, the LTED cells also
showed a marked increase in pHER3 in response to
RAD001, although no corresponding increase in total
HER3 protein expression was evident. The MCF7-
AROM1 cells showed no significant changes in either
HER2 or HER3 under the conditions tested.
RAD001 in combination with 4-OH tamoxifen or letrozole
enhances G1 arrest and increases p27 phosphorylation
and nuclear localization
As mTORC1 is strongly implicated in the regulation of
D-type cyclins [16] and p27 [12], the effect of RAD001 ±
endocrine therapy on cell-cycle progression was assessed.
Changes in the percentage of cells in G2/M were only
modest (data not shown); therefore, we focused our ana-
lysis on S-phase and G1-phase alterations (Figure 4A).
Androstenedione increased the percentage of cells in
S-phase compared with control in both MCF7-AROM1
and BT474-AROM3. RAD001 in combination with letro-
zole or 4-OH tamoxifen increased the number of cells in
G1 versus the monotherapies in both the MCF7-AROM1
(letrozole, 74%, versus letrozole + RAD001, 80%; P =
0.01; 4-OH tamoxifen, 75% versus 4-OH tamoxifen +
RAD001, 80%; P = 0.01) and the BT474-AROM3 (letro-
zole, 77%, versus letrozole + RAD001, 80%; P = 0.1; 4-
OH tamoxifen, 66%, versus 4-OH tamoxifen + RAD001,
80%; P = 0.016). Reciprocal changes were noted for the
treatment effects on S-phase.
In the presence of androstenedione, increased p27ser10
phosphorylation was evident in response to RAD001
and letrozole, as compared with androstenedione alone
in both BT474-AROM3 and MCF7-AROM1. The com-
bination of RAD001 ± either endocrine agent caused a
marked increase in p27ser10 phosphorylation in BT474-
AROM3. Similarly, but to a lesser extent, p27ser10 phos-
phorylation was also increased in MCF7-AROM1 in
response to the combinations. A corresponding decrease
in expression of cyclin D3 and pRb807 in response to
RAD001 ± endocrine therapy was also seen, with Rb
phosphorylation in particular being more profoundly
affected by combination treatment in both MCF7-
AROM1 and BT474-AROM3 (Figure 4B).
AKT can phosphorylate p27 on threonine 157
(p27kip1Thr-157), suppressing nuclear import and subse-
quent p27-driven G1 arrest [34]; hence, confocal micro-
scopy was used to detect nuclear p27. The combination
of RAD001 ± letrozole or 4-OH tamoxifen significantly
increased the number of nuclei positive for p27 com-
pared with monotherapy in both cell lines (Figure 4C).
The effect of RAD001 alone or in combination with
endocrine therapy on ER-transactivation
MCF7-AROM1, BT474-AROM3, and LTED cells were
transiently transfected with an ERE-luciferase reporter
construct and treated with 4-OH tamoxifen or letrozole ±
RAD001 (Figure 5) to assess whether the interactions
between the drugs were related to effects on E-dependent
transactivation. RAD001 had no significant effect on
ER-mediated transactivation in the MCF7-AROM1 cells ±
androstenedione or letrozole compared with the single
agents (Figure 5A). However, 4-OH tamoxifen plus
RAD001 reduced ER-mediated transcription by a further
30% compared with 4-OH tamoxifen alone. In contrast,
in BT474-AROM3 and LTED cells, RAD001 caused a sig-
nificant decrease in ER-mediated transcription in both
the presence and the absence of an estrogenic signal
(Figure 5B, C). Notably, the combination of RAD001 with
both letrozole and/or 4-OH-tamoxifen further suppressed
ER-mediated transactivation compared with the single
agents in the BT474-AROM3 cells.
S6 kinase has been previously associated with the ligand-
independent activation of the ER [35]; we therefore
assessed the effect of RAD001 on the phosphorylation of
ER in the LTED cells modeling acquired resistance.
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Figure 4 RAD001 in combination with 4-OH tamoxifen or letrozole enhances G1 arrest compared with that with monotherapy.
(A) Steroid-depleted MCF7-AROM1 and BT474-AROM3 cells were treated for 24 hours with vehicle, androstenedione (10 nM), 4-OH tamoxifen
(10 nM), or letrozole (100 nM) alone or in combination with RAD001 (2 nM). Cell cycle was monitored with FACS analysis of cells stained with BrdU
and PI. Duplicate plates treated with the drug combination were harvested after 24 hours of treatment. (B) Whole-cell extracts were probed for
phosphorylated p27Kip1, cyclin D3, and phosphorylated Rb. Figures below each panel, where shown, represent semiquantitative changes in protein
expression relative to actin. (C) The effect of drug treatment on p27Kip1 cellular localization was monitored with confocal microscopy. p27Kip1 was
visualized with Alexa 488-conjugated antibodies (green), whereas nuclei were counterstained with TO-PRO-3 (blue). Graphs represent percentage of
total nuclei present (represented by DAPI-stained nuclei). Values shown are mean percentages ± standard deviation.
Martin et al. Breast Cancer Research 2012, 14:R132
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B        
BT474-AROM3 And-mediated  ER/EREBT474-AROM3 basal (No E2) ER/ERE
A        
MCF7-AROM1 And-mediated  ER/EREMCF7-AROM-1 basal (No E2) ER/ERE
C
LTED E2- mediated ER/ERELTED basal (No E2) ER/ERE




0.19 0.15 0.82 0.87 0.70 0.87
1.39 0.01 0.86 0.02 0.11 0.02
1.45 0.00 0.96 0.00 1.07 0.00
LTED
Figure 5 Effects of RAD001 on ER-mediated transcription. (A, B) Cell lines, co-transfected with EREIItkLuc and pCH110, were treated with
RAD001 (2 nM) alone (basal ER-mediated transcription) or, to represent E2-mediated transcription, with a standard 10 nM concentration of
androstenedione ± 4-OH tamoxifen (10 nM) or letrozole (100 nM) ± RAD001 (2 nM). (C) LTED cells were treated similarly, except that E2
(0.01 nM) was used in place of androstenedione. Luciferase activity was normalized by b-galactosidase from co-transfected pCH110. Normalized
luciferase activity from triplicate wells was expressed relative to the vehicle-treated control. Bars represent ± SEM. *P < 0.05, derived from the
comparison of vehicle (DCC) versus RAD001 for basal transcription or the endocrine agent alone versus the combination with RAD001 with
Student unpaired t test. Effects were confirmed in two independent experiments. (D) LTED cells were treated as shown for 24 hours. Western
blot was used to assess changes in phosphorylation of the ER in response to RAD001. Figures below each panel, where shown, represent
semiquantitative changes in protein expression relative to actin.
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RAD001 alone and in combination with E2 ± 4-OH
tamoxifen significantly reduced pERser167 but had no
impact on pERser118 (Figure 5D).
The effect of RAD001 in MCF7-AROM1 and BT474-AROM3
xenograft models
MCF7-AROM1 cells were injected subcutaneously into
immunocompromised mice and maintained under
androstenedione support. With this model, the effects of
increasing doses of RAD001 on tumor growth versus the
vehicle-treated control were studied. The mean fold-
change in tumor volume for each treatment is shown in
Figure 6A. Tumor volumes in the vehicle-treated mice
increased over the study period (mean, 1.68 ± 0.15-fold
on day 20). The mean daily growth rate, expressed as
daily volume change relative to the vehicle group over
the study period, was significantly reduced at concentra-
tions of 2 mg/kg and 10 mg/kg RAD001 compared with
the vehicle (P < 0.05). Based on these data, a concentra-
tion of 2 mg/kg RAD001, which appeared to provide
stable disease, was selected for the combination studies
with letrozole and tamoxifen (Figure 6B). Letrozole
induced tumor stabilization (1.03 ± 0.27 fold-change at
day 20 versus control, 2.03 ± 0.27). Similarly, both
tamoxifen (0.87 ± 0.25) and RAD001 (1.10 ± 0.14)
reduced tumor volume compared with the vehicle-trea-
ted control. Importantly, the combination of RAD001
with letrozole caused tumor regression (fold-change in
tumor volume, 0.59 ± 0.14), whereas the combination
with tamoxifen provided no clear benefit over the single
agents (1.06 ± 0.26). However, the growth rate over the
study period was not significantly different between the
RAD001 and letrozole (P = 0.15) or tamoxifen (P =
0.971) groups. Although the growth rate in the mice trea-
ted with the combination of RAD001 and letrozole was
significantly less than that with the vehicle (P = 0.016),
no statistical difference was found between the combina-
tion and letrozole alone (P = 0.69).
The effects of RAD001 in combination with the endo-
crine agents were also investigated in a second xenograft
model using BT474-AROM3 (ER+, HER2 amp) cells
(Figure 6C). The mean tumor-volume fold change was
2.07 ± 0.7 at day 23 for the vehicle. However, in contrast
to the previous model, neither letrozole nor tamoxifen
reduced tumor volume, and, although not statistically sig-
nificant, a trend was noted toward tamoxifen promoting
tumor growth compared with the vehicle-treated control
arm (fold-change, 2.42 ± 0.33, versus vehicle, 2.07 ± 0.7).
Of note, RAD001 alone induced tumor stabilization
(1.25 ± 0.33 fold-change at day 23 versus control, 2.07 ±
0.7). Assessment of the combination arms revealed no sig-
nificant difference compared with RAD001 as a single
agent (RAD001 versus letrozole + RAD001, P = 0.77;
RAD001 versus tamoxifen + RAD001, P = 0.89).
Furthermore, the combination of RAD001 and tamoxifen
appeared to have less effect than did RAD001 alone,
although this did not approach statistical significance
No significant alterations in body weight were found
between the vehicle and any of the treatment arms (data
not shown). LTED cells were unable to be established as





































Figure 6 Effect of RAD001, letrozole, and tamoxifen, alone or
combination, on the growth of MCF7-AROM1 and BT474-AROM3
xenografts. MCF7-AROM1 xenograft was grown in the presence of
androstenedione. Once tumors reached 7 to 8 mm in diameter, animals
were randomized to receive vehicle, 0.5 mg/kg (n = 6), 2 mg/kg (n = 6),
or 10 mg/kg RAD001 (n = 6). Bars represent ± SEM. (B) MCF7-AROM1
xenografts were grown as described earlier. Once tumors reached 7 to 8
mm in diameter, animals were randomized to receive vehicle (n = 4),
tamoxifen (n = 4), letrozole (n = 5), RAD001 (2 mg/kg) (n = 5), or a
combination of agents (n = 5). (C) BT474-AROM3 grafts were grown as
described earlier. Once tumors reached 7 to 8 mm in diameter, animals
were randomized to receive vehicle (n = 8), tamoxifen (n = 7), letrozole
(n = 8), RAD001 (2 mg/kg) (n = 8), or a combination of agents (n = 8).
Tumors were measured twice weekly, and points represent mean
change in tumor volumes over that of day 0. Bars represent ± SEM.
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Discussion
RAD001 resulted in concentration-dependent decrease
in proliferation in all cell lines tested, most markedly in
the LTED. In combination with endocrine therapy,
RAD001 enhanced the antiproliferative effect and G1-
accumulation compared with monotherapy. This was
associated with pronounced dephosphorylation of Rb
and increased phosphorylation and nuclear accumula-
tion of p27. RAD001 increased pAKT in all circum-
stances, which was associated with increased pHER3.
Furthermore, RAD001 decreased ER transactivation,
suggesting that the efficacy of RAD001 may relate to
interrupting cross-talk between growth-factor signaling
and ER, leading to decreased ER phosphorylation.
Over recent years, a drive has occurred toward the use
of targeted agents for BC treatment. Both in vitro and in
vivo models of endocrine-resistant BC suggest a shift
from the dependence of tumor cells on the steroid-
receptor pathways driving proliferation to dependence
on growth-factor pathways. This allows the resistant
tumor to circumvent the need for steroid hormone
through downregulation of genomic ER function or by
hypersensitivity to low levels of estradiol [36]. The PI3K
pathway is strongly implicated in endocrine resistance,
and agents that target kinases within this network have
received significant interest [37]. A drive has been noted
toward the rational combination of agents that target de
novo resistance or seek to block acquired resistance.
The combination of RAD001 with exemestane was
recently found, in the BOLERO-2 trial [25], to be more
effective than exemestane alone for the treatment of
advanced BC after initial treatment with a nonsteroidal
AI, but few data from laboratory models provide a
mechanistic explanation.
A large body of evidence links the ER and AKT/
mTORC1 pathways. Studies with CCI-779 show inhibi-
tory effects on BC cell lines that either are E2-dependent,
overexpress HER2, or lack expression of PTEN [38].
Further studies showed a good correlation between sensi-
tivity to CCI-779 and AKT expression [39]. More
recently, it was demonstrated that RAD001 in combina-
tion with letrozole was more effective at inhibiting the
androstenedione-driven proliferation of both MCF7 and
T47D breast tumor cells than was either drug alone [40].
Based on these findings, we aimed to assess the efficacy
of RAD001 ± letrozole or 4-OH tamoxifen in vitro and in
vivo in BC cell lines modeling endocrine-sensitive,
acquired, and de novo-resistant disease that is dependent
on HER2 overexpression. RAD001 inhibited the prolifera-
tion of all cell lines tested in a dose-dependent manner
and increased the sensitivity of both BT474-AROM3 and
LTED BC cells to E-deprivation. In the latter case, the
data are analogous to those from the enhanced activity of
RAD001 plus exemestane versus exemestane alone in
BOLERO-2 [25]. Notably, our data in LTED cells indicate
that maintained suppression of estrogens is likely to be
important for the greatest benefit from RAD001. The
LTED cells show markedly increased HER2 expression
compared with MCF7 cells [31] and, along with the
HER2-amplified BT474 cells, suggest that endocrine resis-
tance due to HER2 overexpression may represent a parti-
cularly sensitive phenotype for targeting mTOR. Our data
also imply that tamoxifen plus RAD001 may be an effec-
tive combination in tumors with acquired resistance to
E-deprivation.
The function of ER as a transcription factor is modu-
lated through phosphorylation; we therefore sought to
determine the effect of RAD001 on ER-mediated tran-
scription. Recent reports have shown that mTORC/
S6K1 and ERK1/2/p90RSK contribute nonoverlapping
inputs into ERa activation through Ser167 phosphoryla-
tion [35]. This may account for the reported additive/
synergistic effects of rapamycin and tamoxifen on MCF7
cell survival in vitro [41,42] and the observation that in
tamoxifen-resistant cell lines, co-treatment with rapamy-
cin in vitro or CCI-779 in vivo inhibited mTOR activity
and restored tamoxifen sensitivity [43]. RAD001 signifi-
cantly inhibited E2-mediated ER-transactivation in the
HER-2 expressing cell lines, BT474-AROM3 and LTED,
but not MCF7-AROM1. This would suggest that ER
function may be dependent on cross-talk between
HER2/mTORC/S6K1 and ER in the endocrine-resistant
cell lines. In support of this, inhibition of S6K by
RAD001 significantly reduced phosphorylation of ER
Ser167, in keeping with previous studies [35,44] and
resulted in a modest inhibitory effect on E2-driven
phosphorylation of ER Ser118.
In MCF7-AROM1 xenografts, the combination of
RAD001 and letrozole induced tumor regression, as
opposed to the stabilization observed with the mono-
therapies, although analysis of growth rates did not show
this to be statistically significant. Moreover, combination
with 4OH-tamoxifen provided no clear benefit over the
single agents. These data are consistent with the in vitro
data with MCF7-AROM1 cells, where more profound
combination effects were observed with RAD001 in com-
bination with letrozole, supporting a combination of AI
rather than tamoxifen with RAD001 for the first-line
treatment of ER+ BC.
In the BT474-AROM3 xenograft, RAD001 alone was
superior to both letrozole and tamoxifen when provided
as monotherapies, and no additional benefit was seen by
treatment with RAD001 in combination with letrozole or
tamoxifen. The lack of a combination effect may reflect
the complexity of the tumor/stroma environment, which
cannot be recapitulated in vitro, or may indicate that
alternative doses and administration schedules should be
evaluated. However, based on RAD001-associated
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increases in AKT phosphorylation in vitro, which was
particularly evident with the combination treatments in
this model, compensatory survival signals may be respon-
sible for restricting the efficacy of the combination treat-
ments in vivo. Inhibition of mTORC1 is known to induce
upstream receptor tyrosine kinase signaling and to acti-
vate AKT [33]. Furthermore, inhibition of mTORC1 also
leads to activation of the ERK signaling pathway [45].
This may have clinical implications, as some tumors
from patients treated with RAD001 showed an increase
in phospho-AKT and/or phospho-ERK, a phenomenon
postulated to explain the comparatively modest clinical
activity of rapamycins as single agents [33,45,46]. The
absence of regression of the BT474 tumors in response
to any of the treatments, although of mechanistic inter-
est, has limited clinical significance, given that HER2-
amplified tumors are now treated with HER2-targeted
therapy, such as trastuzumab.
Further to address the potential escape routes from
RAD001, we characterized the effect of the treatments
on the major signaling pathways in the cell-line models.
The mTOR-activated kinase S6K1 is known to phos-
phorylate and destablize IRS1 and IRS2 in insulin-like
growth factor (IGF)-responsive cells [33]. mTOR inhibi-
tion reduces S6K1 activity, causing an increase in IRS1/
2 and enhanced activation of IGFR1-dependent Akt
activity [33]. Of note, the IGF pathway regulates ER
function via S6K [44], providing a strong link between
mTOR and ER activity. The LTED cells showed a slight,
but expected, increase in IRS1 in response to RAD001.
However, both the LTED and BT474-AROM3 showed
increased pHER3, which also correlated with enhanced
pAKT. Previous studies have shown that the HER3/
PI3K signaling pathway increases expression of survivin,
an inhibitor of apoptosis in HER2-expressing cell lines,
and is associated with resistance to laptinib and che-
motherapy [47,48]. Although RAD001 has a substantial
impact on the HER2-overexpressing cell lines, the
enhanced HER3 signaling may impede its long-term effi-
cacy. The activation of pAKT is recognized as a likely
escape route from inhibition of mTORC1, and the data
from this study indicate that this persists in combination
with endocrine therapy. Dual targeting of mTOR and
upstream HER pathways, along with endocrine therapy,
is likely to be more effective.
Conclusions
RAD001 in combination with endocrine therapy provides
little further benefit compared with endocrine therapy
alone in a model of hormone-sensitive ER+ BC. In contrast,
RAD001 was effective as monotherapy in ER+ endocrine-
resistant cells based on HER2 overexpression or amplifica-
tion, and in those cells with acquired resistance, maintained
E-deprivation was important for maximal effectiveness of
RAD001. The benefit may reflect interruption of growth
factor-dependent transactivation of ER. The results provide
mechanistic support for recent positive clinical data on the
combination of RAD001 and endocrine therapy, as well as
data on potential routes of escape through enhanced
HER2/3 signaling, which merit investigation for further
improvements in treatment efficacy.
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Additional File 1: Comparative expression of HER2 in LTED versus
BT474 cells. Whole-cell extracts from MCF7, LTED, and BT474 cells were
resolved with SDS-PAGE and immunoblotted for expression of HER2 and
actin.
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